Drug Profile
Morphothiadine - HEC Pharm
Alternative Names: GLS4; Morphothiadin; Morphothiadine mesilate; Morphothiadine mesylateLatest Information Update: 20 May 2021
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class Antivirals; Bromobenzenes; Esters; Fluorinated hydrocarbons; Mesylates; Morpholines; Pyrimidines; Small molecules; Thiazoles
- Mechanism of Action Hepatitis B virus replication inhibitors; Viral core protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Hepatitis B
Most Recent Events
- 12 Mar 2021 Sunshine Lake Pharma completes a phase I trial for Hepatitis B (In volunteers, combination therapy) in China (PO) (NCT04551261)
- 03 Mar 2021 Phase II development is still ongoing for Hepatitis B (Combination therapy) in China (NCT04147208)
- 10 Jan 2021 Sunshine Lake Pharma initiates enrolment in a phase I trial for Hepatitis B (In volunteers, combination therapy) in China (PO) (NCT04551261)